Alliances of leading biopharmaceutical companies as a strategic axis for the development of anti-COVID-19 vaccines
Keywords:
COVID-19, pandemic, virus, vaccine, SARS-CoV-2Abstract
Alliances of leading biopharmaceutical companies as a strategic axis for the development of anti-COVID-19 vaccinesDownloads
Download data is not yet available.
References
1. ClinicalOmics. NIH to Launch Public-Private Effort to Accelerate Development of COVID-19 Vaccines, Treatments. ClinicalOmics. 2020 [acceso: 27/11/2020]. Disponible en: https://www.clinicalomics.com/topics/patient-care/therapeutics/nih-to-launch-public-private-effort-to-accelerate-development-of-covid-19-vaccines-treatments/
2. Lambert P, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020 [acceso: 24/11/2020]; 38(31):4783-91. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0264410X2030709X
3. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. N Engl J Med. 2020[acceso: 23/11/2020]; 383(10):63. Disponible en: https://www.nejm.org/doi/10.1056/NEJMp2020076
4. Organización Mundial de la Salud. Prevención y control de infecciones durante la atención médica cuando se sospecha una nueva infección por coronavirus: Guía Provisional. Ginebra: WHO. 2020[acceso: 11/03/2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/330685/9789240001114-
5. World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO. 2020 [acceso: 23/11/2020]. Disponible en: https://www.whoint/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
6 . Ministerio de Salud Pública de Cuba. Plan para la prevención y control del nuevo coronavirus (COVID-19). La Habana: Minsap. 2020. [acceso: 23/11/2020]. Disponible en: https://salud.msp.gob.cu/para-prevenir-yenfrentar-el-nuevo-coronavirus-la-participacion-popular-es-esencial/
2. Lambert P, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020 [acceso: 24/11/2020]; 38(31):4783-91. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0264410X2030709X
3. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. N Engl J Med. 2020[acceso: 23/11/2020]; 383(10):63. Disponible en: https://www.nejm.org/doi/10.1056/NEJMp2020076
4. Organización Mundial de la Salud. Prevención y control de infecciones durante la atención médica cuando se sospecha una nueva infección por coronavirus: Guía Provisional. Ginebra: WHO. 2020[acceso: 11/03/2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/330685/9789240001114-
5. World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO. 2020 [acceso: 23/11/2020]. Disponible en: https://www.whoint/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
6 . Ministerio de Salud Pública de Cuba. Plan para la prevención y control del nuevo coronavirus (COVID-19). La Habana: Minsap. 2020. [acceso: 23/11/2020]. Disponible en: https://salud.msp.gob.cu/para-prevenir-yenfrentar-el-nuevo-coronavirus-la-participacion-popular-es-esencial/
Published
2021-04-01
How to Cite
1.
Rodríguez Perón JM, Rodríguez Izquierdo MM. Alliances of leading biopharmaceutical companies as a strategic axis for the development of anti-COVID-19 vaccines. Rev Cubana Med Milit [Internet]. 2021 Apr. 1 [cited 2025 Jan. 14];50(2):e02101193. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/1193
Issue
Section
Editorial
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
